Resveratrol exerts anti-obesity effects in high-fat diet obese mice and displays differential dosage effects on cytotoxicity, differentiation, and lipolysis in 3T3-L1 cells

Endocrine Journal

Volumn 63, Issue 2, 2016, Pages 169-178

  Chang, Chih Chun ^a   Lin, Keng Yang ^b,c   Peng, Kang Yu ^b   Day, Yuan Ji ^d   Hung, Li Man ^b,c  

^a FAR EASTERN MEMORIAL HOSPITAL   (Taiwan)

^b CHANG GUNG UNIVERSITY COLLEGE OF MEDICINE   (Taiwan)

^c CHANG GUNG UNIVERSITY   (Taiwan)

^d CHANG GUNG MEMORIAL HOSPITAL   (Taiwan)

Author keywords

Adipogenic differentiation; Cytotoxicity; Lipolysis; Obesity; Resveratrol

Indexed keywords

CHOLESTEROL; FATTY ACID; PERILIPIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; RESVERATROL; TRIACYLGLYCEROL; TUMOR NECROSIS FACTOR ALPHA; ANTIOBESITY AGENT; STILBENE DERIVATIVE;

3T3 CELL LINE; ADIPOCYTE; ADIPOGENESIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIOBESITY ACTIVITY; ARTICLE; BODY WEIGHT; CELL DIFFERENTIATION; CELL MEDIATED CYTOTOXICITY; CELL PROLIFERATION; CELL VIABILITY; CHOLESTEROL BLOOD LEVEL; CONCENTRATION RESPONSE; CONTROLLED STUDY; DIET SUPPLEMENTATION; DOWN REGULATION; DRUG ACTIVITY; FATTY ACID BLOOD LEVEL; LIPID DIET; LIPOLYSIS; MOUSE; NONHUMAN; OBESITY; PROADIPOCYTE; PROTEIN EXPRESSION; THERAPY EFFECT; TREATMENT DURATION; TRIACYLGLYCEROL BLOOD LEVEL; WEIGHT GAIN; WESTERN BLOTTING; 3T3-L1 CELL LINE; ANIMAL; C57BL MOUSE; CELL DEATH; DOSE RESPONSE; DRUG EFFECTS; MALE; METABOLISM; MOUSE MUTANT;

3T3-L1 CELLS; ADIPOGENESIS; ANIMALS; ANTI-OBESITY AGENTS; CELL DEATH; CELL DIFFERENTIATION; DIET, HIGH-FAT; DOSE-RESPONSE RELATIONSHIP, DRUG; LIPOLYSIS; MALE; MICE; MICE, INBRED C57BL; MICE, OBESE; OBESITY; STILBENES;

EID: 84959368437     PISSN: 09188959     EISSN: 13484540     Source Type: Journal    
DOI: 10.1507/endocrj.EJ15-0545     Document Type: Article

References (41)

1. Kannel WB, Cupples LA, Ramaswami R, Stokes J, Kreger BE, et al. (1991) Regional obesity and risk of cardiovascular disease; the Framingham Study. J Clin Epidemiol 44: 183-190.
2. Field AE, Coakley EH, Must A, Spadano JL, Laird N, et al. (2001) Impact of overweight on the risk of developing common chronic diseases during a 10-year period. Arch Intern Med 161: 1581-1586.
3. Ogden CL, Carroll MD, Curtin LR, McDowell MA, Tabak CJ, et al. (2006) Prevalence of overweight and obesity in the United States, 1999-2004. JAMA 295: 1549-1555.
4. Calle EE, Rodriguez C, Walker-Thurmond K, Thun MJ (2003) Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. N Engl J Med 348: 1625-1638.
5. Gregoire FM, Smas CM, Sul HS (1998) Understanding adipocyte differentiation. Physiol Rev 78: 783-809.
6. He Y, Li Y, Zhao T, Wang Y, Sun C (2013) Ursolic acid inhibits adipogenesis in 3T3-L1 adipocytes through LKB1/AMPK pathway. PLoS One 8: e70135.
7. Tontonoz P, Hu E, Spiegelman BM (1994) Stimulation of adipogenesis in fibroblasts by PPAR gamma 2, a lipid-activated transcription factor. Cell 79: 1147-1156.
8. Rosen ED, Walkey CJ, Puigserver P, Spiegelman BM (2000) Transcriptional regulation of adipogenesis. Genes Dev 14: 1293-1307.
9. Zhang B, Berger J, Zhou G, Elbrecht A, Biswas S, et al. (1996) Insulin-and mitogen-activated protein kinasemediated phosphorylation and activation of peroxisome proliferator-activated receptor gamma. J Biol Chem 271: 31771-31774.
10. Rangwala SM, Rhoades B, Shapiro JS, Rich AS, Kim JK, et al. (2003) Genetic modulation of PPARgamma phosphorylation regulates insulin sensitivity. Dev Cell 5: 657-663.
11. Shiomi Y, Yamauchi T, Iwabu M, Okada-Iwabu M, Nakayama R, et al. (2015) A novel Peroxisome Proliferator-activated Receptor (PPAR)α agonist and PPARγ antagonist, Z-551, ameliorates high-fat dietinduced obesity and metabolic disorders in mice. J Biol Chem 290: 14567-14581.
12. Gouranton E, Romier B, Marcotorchino J, Tourniaire F, Astier J, et al. (2014) Visfatin is involved in TNFα-mediated insulin resistance via an NAD(+)/Sirt1/PTP1B pathway in 3T3-L1 adipocytes. Adipocyte 3: 180-189.
13. Finucane OM, Reynolds CM, McGillicuddy FC, Roche HM (2012) Insights into the role of macrophage migration inhibitory factor in obesity and insulin resistance. Proc Nutr Soc 71: 622-633.
14. Huang JP, Huang SS, Deng JY, Chang CC, Day YJ, et al. (2010) Insulin and resveratrol act synergistically, preventing cardiac dysfunction in diabetes, but the advantage of resveratrol in diabetics with acute heart attack is antagonized by insulin. Free Radic Biol Med 49: 1710-1721.
15. Akar F, Pektas MB, Tufan C, Soylemez S, Sepici A, et al. (2011) Resveratrol shows vasoprotective effect reducing oxidative stress without affecting metabolic disturbances in insulin-dependent diabetes of rabbits. Cardiovasc Drugs Ther 25: 119-131.
16. Xu Y, Nie L, Yin YG, Tang JL, Zhou JY, et al. (2012) Resveratrol protects against hyperglycemia-induced oxidative damage to mitochondria by activating SIRT1 in rat mesangial cells. Toxicol Appl Pharmacol 259: 395-401.
17. Ghanim H, Sia CL, Abuaysheh S, Korzeniewski K, Patnaik P, et al. (2010) An antiinflammatory and reactive oxygen species suppressive effects of an extract of Polygonum cuspidatum containing resveratrol. J Clin Endocrinol Metab 95: E1-E8.
18. Palsamy P, Sivakumar S, Subramanian S (2010) Resveratrol attenuates hyperglycemia-mediated oxidative stress, proinflammatory cytokines and protects hepatocytes ultrastructure in streptozotocin-nicotinamide-induced experimental diabetic rats. Chem Biol Interact 186: 200-210.
19. Das DK, Sato M, Ray PS, Maulik G, Engelman RM, et al. (1999) Cardioprotection of red wine: role of polyphenolic antioxidants. Drugs Exp Clin Res 25: 115-120.
20. Wu JM, Wang ZR, Hsieh TC, Bruder JL, Zou JG, et al. (2001) Mechanism of cardioprotection by resveratrol, a phenolic antioxidant present in red wine. Int J Mol Med 8: 3-17.
21. Delmas D, Jannin B, Latruffe N (2005) Resveratrol: preventing properties against vascular alterations and ageing. Mol Nutr Food Res 49: 377-395.
22. Ruan BF, Lu XQ, Song J, Zhu HL (2012) Derivatives of resveratrol: potential agents in prevention and treatment of cardiovascular disease. Curr Med Chem 19: 4175-4183.
23. Bishayee A (2009) Cancer prevention and treatment with resveratrol: from rodent studies to clinical trials. Cancer Prev Res(Phila) 2: 409-418.
24. Whitlock NC, Baek SJ (2012). The anticancer effects of resveratrol: modulation of transcription factors. Nutr Cancer 64: 493-502.
25. Juan ME, Alfaras I, Planas JM (2012) Colorectal cancer chemoprevention by trans-resveratrol. Pharmacol Res 65: 584-591.
26. Albani D, Polito L, Signorini A, Forloni G (2010) Neuroprotective properties of resveratrol in different neurodegenerative disorders. Biofactors 36: 370-376.
27. Li F, Gong Q, Dong H, Shi J (2012) Resveratrol, a neuroprotective supplement for Alzheimer’s disease. Curr Pharm Des 18: 27-33.
28. Lagouge M, Argmann C, Gerhart-Hines Z, Meziane H, Lerin C, et al. (2006) Resveratrol improves mitochondrial function and protects against metabolic disease by activating SIRT1 and PGC-1alpha. Cell 127: 1109-1122.
29. Liu L, Wang Y, Lam KS, Xu A (2008) Moderate wine consumption in the prevention of metabolic syndrome and its related medical complications. Endocr Metab Immune Disord Drug Targets 8: 89-98.
30. Beaudeux JL, Nivet-Antoine V, Giral P (2010) Resveratrol: a relevant pharmacological approach for the treatment of metabolic syndrome? Curr Opin Clin Nutr Metab Care 13: 729-736.
31. Xia X, Weng J (2010) Targeting metabolic syndrome: candidate natural agents. J Diabetes 2: 243-249.
32. Costa Cdos S, Rohden F, Hammes TO, Margis R, Bortolotto JW, et al. (2011) Resveratrol upregulated SIRT1, FOXO1, and adiponectin and downregulated PPARγ1-3 mRNA expression in human visceral adipocytes. Obes Surg 21: 356-361.
33. Baile CA, Yang JY, Rayalam S, Hartzell DL, Lai CY, et al. (2011) Effect of resveratrol on fat mobilization. Ann N Y Acad Sci 1215: 40-47.
34. Walle T, Hsieh F, DeLegge MH, Oatis JE Jr, Walle UK (2004) High absorption but very low bioavailability of oral resveratrol in humans. Drug Metab Dispos 32: 1377-1382.
35. Rayalam S, Della-Fera MA, Yang JY, Park HJ, Ambati S, et al. (2007) Resveratrol potentiates genistein’s antiadipogenic and proapoptotic effects in 3T3-L1 adipocytes. J Nutr 137: 2668-2673.
36. Hu P, Zhao L, Chen J (2015) Physiologically achievable doses of resveratrol enhance 3T3-L1 adipocyte differentiation. Eur J Nutr 54: 569-579.
37. Carpene C, Gomez-Zorita S, Deleruyelle S, Carpene MA (2015) Novel strategies for preventing diabetes and obesity complications with natural polyphenols. Curr Med Chem 22: 150-164.
38. Bai L, Pang WJ, Yang YJ, Yang GS (2008) Modulation of Sirt1 by resveratrol and nicotinamide alters proliferation and differentiation of pig preadipocytes. Mol Cell Biochem 307: 129-140.
39. Fisher-Posovszky P, Kukulus V, Tews D, Unterkircher T, Debatin KM, et al. (2010) Resveratrol regulates human adipocyte number and function in a Sirt1-dependent manner. Am J Clin Nutr 92: 5-15.
40. Szkudelska K, Nogowski L, Szkudelski T (2009) Resveratrol, a naturally occurring diphenolic compound, affects lipogenesis, lipolysis and the antilipolytic action of insulin in isolated rat adipocytes. J Steroid Biochem Mol Biol 113: 17-24.
41. Lasa A, Schweiger M, Kotzbeck P, Churruca I, Simón E, et al. (2012) Resveratrol regulates lipolysis via adipose triglyceride lipase. J Nutr Biochem 23: 379-384.